Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

BRISBANE, Australia, March 11 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced the commencement of its global phase 3 study investigating PI-88 as an adjuvant treatment for primary liver cancer (hepatocellular carcinoma, HCC) following curative resection with the first patient having been randomized onto the study. The study is known globally as PATHWAY (PI-88 in the adjuvant treatment of HCC). The first patient to enter the trial is from Singapore.

Dr. Ronnie Poon, Ph.D., M.D., global lead investigator for PATHWAY, commented, "My colleagues and I are encouraged by the phase 2 data that Progen has generated for PI-88 in this challenging disease, for which there are no approved treatment options. If PATHWAY is successful, PI-88 could change the standard of care for resected liver cancer patients."

PATHWAY, a double-blinded, placebo-controlled study, has been designed to establish the efficacy and safety of PI-88 in the post resection liver cancer setting. The trial will recruit approximately 600 patients at about 65-70 hospitals in more than a dozen countries. Disease-free survival, a measure of the average length of time that patients remain free of tumor recurrence, is the primary endpoint. Upon completion of this trial, the results are expected to form the basis of global registration filings for PI-88.

Justus Homburg, Progen's CEO, said, "Commencement of this trial represents a significant milestone for Progen. We have designed this trial in collaboration with world experts in this field of medicine, and with USA FDA Fast Track and EU EMEA Orphan Drug Status, its initiation underscores our commitment to making this important drug rapidly available to patients who currently have few treatment options available."

Liver cancer is one of the top five causes of cancer deaths in the world, with over half a million new cases per year. Although surgical resection is one of the few treatme
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in ... announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products ... Society (NASS) 2009 Annual Meeting, taking place November 10th through ... been used in 40 spinal surgeries in the ...
... Inc. (Nasdaq: VVUS ) today announced that Timothy Morris, chief ... Lazard Capital Markets 6th Annual Healthcare Conference. , The VIVUS presentation ... on Wednesday, November 18, 2009 at 1:45 p.m. ET. A ... at http://ir.vivus.com . , About VIVUS ...
Cached Medicine Technology:Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 2Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 3Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 4Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 5VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:8/31/2015)... , ... August 31, 2015 , ... ... introduces the Talent Management Division , a department devoted to helping organizations ... department. Talent management goes beyond selection, and The Brooks Group believes in offering ...
(Date:8/31/2015)... ... 2015 , ... According to book reviewer Angie Santangeloon , Dr. ... Cancer is an excellent resource for everyone since one in three persons will ... in explaining what cancer is in a easy to understand medically accurate way. The ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... excited to establish its first Digital Hub in North America, now open in ... selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and beautiful ...
(Date:8/31/2015)... CO (PRWEB) , ... August 31, 2015 , ... Adult ... potential Denver area dermatology patients of the treatments and services available to ... patients by utilizing an innovative and ‘responsive design’ that allows visitors to view the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... TheHardwareCity.com is pleased ... tools set . , These home repair tool sets are manufactured by Allied Tools. ... around the house. The tri-fold tool set allows yard and house work to be ...
Breaking Medicine News(10 mins):Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2
... , NANJING, China, June 19 ... a leading manufacturer and supplier of branded generic and,innovative ... annual,report on Form 20-F for the year ended December ... 18, 2009. The annual report can be accessed on,the ...
... ... will be introducing ten (10) new products at the 26th Annual ASMBS scheduled for June ... ... introducing ten (10) new products at the 26th Annual ASMBS scheduled for June 21-26 in ...
... Georgia facility to offer new choice in cancer treatment with fully ... 18 Cancer Treatment Centers of America (CTCA) announced today that ... cancer treatment hospital that will serve patients in the Southeast and ... View the Multimedia News Release, go to: http://www.prnewswire.com/mnr/cancercenter/38837 ...
... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
... , Senator John D. Rockefeller IV and Senator Bob Corker ... YORK, June 18 The American Society of Interventional ... All Schedules Prescription Electronic Reporting (NASPER) Act has received ... Virginia and Senator Bob Corker of Tennessee. , ...
... (Nasdaq: MEDQ ) has announced it has added ... Chief Information Officer. , , "As CIO, ... and development resources are aligned with its strategic and operational ... for profitable revenue and market share growth," says Peter Masanotti, ...
Cached Medicine News:Health News:Bariatric Advantage to Introduce Ten (10) New Products at ASMBS 2Health News:VIDEO: Cancer Treatment Centers of America Selects Site in GA for Proposed Hospital Serving Patients in Southeast 2Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 3Health News:MedQuist Adds Kevin Piltz as New Chief Information Officer 2
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... is as easy as 1-2-3: just three simple ... satisfaction with rapid information before they leave your ... with the appropriate therapy; no more follow-up appointments ... Strep A Test is a rapid immunochromatographic assay ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: